Name | Number of supported studies | Average coverage | |
---|---|---|---|
platelet | 7 studies | 24% ± 8% | |
fibroblast | 6 studies | 22% ± 7% | |
astrocyte | 5 studies | 28% ± 7% | |
classical monocyte | 4 studies | 26% ± 10% | |
neuron | 4 studies | 27% ± 11% | |
pericyte | 4 studies | 19% ± 2% | |
amacrine cell | 4 studies | 38% ± 2% | |
retina horizontal cell | 4 studies | 28% ± 7% | |
GABAergic neuron | 4 studies | 42% ± 16% | |
oligodendrocyte precursor cell | 4 studies | 23% ± 7% | |
oligodendrocyte | 4 studies | 24% ± 1% | |
myofibroblast cell | 3 studies | 26% ± 8% | |
retinal ganglion cell | 3 studies | 47% ± 23% | |
glutamatergic neuron | 3 studies | 55% ± 8% | |
dendritic cell | 3 studies | 30% ± 9% | |
megakaryocyte | 3 studies | 30% ± 10% | |
plasmacytoid dendritic cell | 3 studies | 21% ± 6% | |
interneuron | 3 studies | 38% ± 19% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 40% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 1601.72 | 2639 / 2642 | 100% | 26.05 | 705 / 705 |
adrenal gland | 99% | 1336.76 | 256 / 258 | 100% | 34.35 | 229 / 230 |
skin | 99% | 808.98 | 1798 / 1809 | 99% | 34.27 | 468 / 472 |
kidney | 100% | 738.81 | 89 / 89 | 97% | 14.44 | 877 / 901 |
prostate | 99% | 803.11 | 243 / 245 | 97% | 12.19 | 489 / 502 |
ovary | 99% | 728.09 | 179 / 180 | 95% | 8.66 | 409 / 430 |
thymus | 98% | 568.16 | 643 / 653 | 93% | 7.49 | 560 / 605 |
breast | 100% | 899.41 | 459 / 459 | 89% | 9.12 | 1000 / 1118 |
lung | 98% | 638.35 | 567 / 578 | 86% | 7.52 | 997 / 1155 |
bladder | 100% | 1182.48 | 21 / 21 | 83% | 6.99 | 420 / 504 |
intestine | 90% | 1170.92 | 873 / 966 | 86% | 7.89 | 453 / 527 |
esophagus | 83% | 838.19 | 1196 / 1445 | 87% | 8.04 | 159 / 183 |
uterus | 100% | 1163.14 | 170 / 170 | 63% | 8.26 | 288 / 459 |
stomach | 67% | 651.73 | 241 / 359 | 87% | 9.00 | 250 / 286 |
pancreas | 44% | 132.95 | 145 / 328 | 97% | 11.93 | 173 / 178 |
blood vessel | 100% | 1719.81 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 871.25 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.85 | 1 / 1 |
adipose | 100% | 1113.46 | 1203 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 30.26 | 79 / 80 |
peripheral blood | 99% | 1737.12 | 916 / 929 | 0% | 0 | 0 / 0 |
muscle | 98% | 615.88 | 790 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 1098.55 | 839 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 7.04 | 26 / 29 |
liver | 19% | 57.54 | 43 / 226 | 60% | 5.98 | 242 / 406 |
tonsil | 0% | 0 | 0 / 0 | 47% | 2.69 | 21 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050765 | Biological process | negative regulation of phagocytosis |
GO_0046856 | Biological process | phosphatidylinositol dephosphorylation |
GO_0031902 | Cellular component | late endosome membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0030670 | Cellular component | phagocytic vesicle membrane |
GO_0034597 | Molecular function | phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PIP4P2 |
Protein name | Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase (Type 2 PtdIns-4,5-P2 4-Ptase) (EC 3.1.3.78) (PtdIns-4,5-P2 4-Ptase II) (Transmembrane protein 55A) Phosphatidylinositol-4,5-bisphosphate 4-phosphatase (EC 3.1.3.78) Phosphatidylinositol-4,5-bisphosphate 4-phosphatase 2 |
Synonyms | TMEM55A |
Description | FUNCTION: Catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) to phosphatidylinositol-4-phosphate (PtdIns-4-P) . Does not hydrolyze phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-bisphosphate, inositol 3,5-bisphosphate, inositol 3,4-bisphosphate, phosphatidylinositol 5-monophosphate, phosphatidylinositol 4-monophosphate and phosphatidylinositol 3-monophosphate . Negatively regulates the phagocytosis of large particles by reducing phagosomal phosphatidylinositol 4,5-bisphosphate accumulation during cup formation (By similarity). . FUNCTION: Catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) to phosphatidylinositol-4-phosphate (PtdIns-4-P). . FUNCTION: Catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) to phosphatidylinositol-4-phosphate (PtdIns-4-P). . |
Accessions | ENST00000285419.8 E5RJC2 ENST00000518869.1 Q8N4L2 ENST00000520014.1 ENST00000520709.5 ENST00000630164.1 E5RIY0 E5RFT4 ENST00000518359.5 E5RIP9 |